Fibroblast growth factor 21 alleviates unilateral ureteral obstruction-induced renal fibrosis by inhibiting Wnt/β-catenin signaling pathway
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 2024
DOI: 10.1016/j.bbamcr.2023.119620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2024. Verfasst von Wenhui Zhong und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Nanfang Hospital, Southern Medical University, …. Hauptthemen laut MEDLINE: Ureteral Obstruction, Kidney Diseases, Fibroblast Growth Factors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Fibroblast growth factor 21 (FGF21) is a key regulator of energy metabolism. Recent studies suggested that serum FGF21 levels increase with declining renal function. However, the link between FGF21 and kidney diseases and the direct effect of FGF21 in renal fibrosis remains unclear. In this study, FGF21 was upregulated in unilateral ureteral obstruction (UUO)-induced renal fibrosis and cellular fibrosis induced by transforming growth factor-β, and renal expression of FGF21 was positively correlated with fibrosis markers. Additionally, FGF21 was regulated by Wnt/β-catenin signaling pathway. The knockdown and overexpression of FGF21 in mouse tubular epithelial cells demonstrated that FGF21 alleviates renal fibrosis by inhibiting the Wnt/β-catenin signaling pathway. To investigate the effect of FGF21 on renal fibrosis in vivo, we established an overexpression model by injecting the plasmid in mice and found that FGF21 overexpression relieved UUO-induced renal fibrosis and renal inflammatory response. Taken together, FGF21 is upregulated with the activation of Wnt/β-catenin signaling pathway and alleviates renal fibrosis by inhibiting the activation of Wnt/β-catenin signaling pathway in a negative feedback mode. These results provide a new understanding for the source of elevated serum FGF21 in patients with chronic kidney disease and prove that FGF21 is a direct inhibitor of the progression of renal fibrosis, thus providing novel therapeutic intervention insights for renal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Nanfang Hospital, Southern Medical University, 510515 Guangzhou, China; Guangdong Provincial Institute of Nephrology,…
- Xingguo Hospital Affiliated to Gannan Medical University, Xingguo People's Hospital, 342400 Ganzhou, China. Electronic address: 836485681@qq.com.
- Xingguo Hospital Affiliated to Gannan Medical University, Xingguo People's Hospital, 342400 Ganzhou, China.
Zitieren
APA
Zhong, W., Jiang, Y., Wang, H., Luo, X., Zeng, T., Huang, H., Xiao, L., Jia, N., & Li, A. (2024). Fibroblast growth factor 21 alleviates unilateral ureteral obstruction-induced renal fibrosis by inhibiting Wnt/β-catenin signaling pathway. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. https://doi.org/10.1016/j.bbamcr.2023.119620
Vancouver
Zhong W, Jiang Y, Wang H, Luo X, Zeng T, Huang H, et al. Fibroblast growth factor 21 alleviates unilateral ureteral obstruction-induced renal fibrosis by inhibiting Wnt/β-catenin signaling pathway. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2024. doi:10.1016/j.bbamcr.2023.119620
BibTeX
@article{Zhong2024,
author = {Zhong, Wenhui and Jiang, Yuheng and Wang, Huizhen and Luo, Xiang and Zeng, Tao and Huang, Huimi and Xiao, Ling and Jia, Nan and Li, Aiqing},
title = {Fibroblast growth factor 21 alleviates unilateral ureteral obstruction-induced renal fibrosis by inhibiting Wnt/β-catenin signaling pathway},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Cell Research},
year = {2024},
doi = {10.1016/j.bbamcr.2023.119620}
}
EUVIMED